4 citations
,
July 2024 in “Biomolecules” This review suggests systemic changes in polycystic ovary syndrome may increase the risk of neurodegeneration, potentially linking it to Alzheimer's disease through common pathways affecting tryptophan metabolism.
4 citations
,
February 2024 in “Anais Brasileiros de Dermatologia”
3 citations
,
July 2015 in “oURspace (University of Regina)” This thesis presents research conducted in partial fulfillment of a Master's degree in Software Systems Engineering but does not report new empirical findings.
2 citations
,
March 2025 in “Journal of Translational Autoimmunity” This study reports that AhR pathway expression is significantly reduced in lymphocytes of alopecia areata patients, suggesting its potential as a diagnostic marker and therapeutic target.
2 citations
,
May 2023 in “Anais Brasileiros de Dermatologia” 2 citations
,
January 2023 in “Anais Brasileiros de Dermatologia” 2 citations
,
May 2022 in “International Journal of Impotence Research” This pharmacovigilance study found strong disproportionality signals suggesting an association between finasteride and Peyronie's disease-related clinical features, but the evidence does not confirm a causal link.
2 citations
,
September 2010 in “Acta Ophthalmologica” The study concluded that all parts of the normal human Meibomian gland ductal system show signs of early keratinisation, supporting the idea that these glands are akin to "hair follicles without a hair shaft.
2 citations
,
July 2018 in “Our Dermatology Online” This case report documents the first known instance of nevoid hyperkeratosis of the nipple and areola with unilateral presentation in a Saudi female, diagnosed through clinical evaluation and biopsy.
1 citations
,
January 2026 in “Journal of Pharmaceutical Analysis” This review highlights the potential of natural compounds like terpenoids, flavonoids, and polyphenols in promoting hair regrowth for those with alopecia areata by activating growth pathways and modulating immune responses, but calls for further research to confirm their therapeutic utility.
1 citations
,
January 2025 in “Molecules” This review reported that while glycyl-L-histidyl-L-lysine tripeptide copper complex (GHK–Cu) has limited skin permeation when used alone, liposomes may enhance its absorption, but there is limited research on this aspect, highlighting a need for further studies.
1 citations
,
November 2024 in “Saudi Pharmaceutical Journal” This study suggests that while adding baricitinib to formularies may increase costs for government hospitals, it could expand treatment options and potentially improve outcomes for patients with AA. Further analyses are recommended to assess its cost-effectiveness in terms of outcomes improvement.
1 citations
,
September 2024 in “Actas Dermo-Sifiliográficas” In this retrospective study from five Colombian cities, researchers detailed the clinical characteristics of 562 alopecia areata patients, noting that multiple plaques and the patchy subtype were common, with steroid injections frequently used as treatment.
1 citations
,
November 2023 in “Anais Brasileiros de Dermatologia” This study suggests that the ADIPOQ gene polymorphism may influence the risk of alopecia areata in Egyptians, with adiponectin levels potentially serving as a marker for hair loss severity.
1 citations
,
September 2023 in “Medicine” In this study, the ABO/Rh blood group distribution in individuals with polycystic ovary syndrome was similar to that of healthy individuals, and there was no link with clinical or biochemical factors of PCOS.
May 2026 in “Scientific Reports” This study found that kukui nut oil (AMS oil) promotes hair growth in human hair follicle cultures by increasing PGF2α levels and activating Nrf2 signaling, and a human trial confirmed its efficacy in enhancing eyelash growth.
August 2026 in “Anais Brasileiros de Dermatologia” In this case report, a 24-year-old woman with Down syndrome effectively managed coexisting alopecia areata and hidradenitis suppurativa using upadacitinib, following partial success with previous treatments.
August 2026 in “Human Immunology” July 2026 in “Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms” June 2026 in “Comprehensive Psychoneuroendocrinology” This study explored the relationship between menopause symptoms and hair cortisol concentrations among midlife Latinas, finding that vasomotor symptoms were associated with higher hair cortisol levels, suggesting a link warranting further investigation with larger sample sizes and multiple time points.
May 2026 in “Current Opinion in Pharmacology”
March 2026 in “Journal of Translational Autoimmunity” In this study using a mouse model with alopecia areata, the researchers found that ruxolitinib enhances hair regrowth by inhibiting the JAK-STAT signaling pathway, reducing inflammation and oxidative stress, and decreasing apoptosis, which supports its clinical effectiveness in treating this condition.
March 2026 in “Microchemical Journal” July 2025 in “Clinical Medicine” In this institution-based randomized trial, oral betamethasone mini-pulse therapy for alopecia areata showed a faster therapeutic response compared to oral tofacitinib, as measured by trichoscopic changes and achievement of 50% hair regrowth.
April 2025 in “Asian Journal of Surgery” January 2024 in “Elsevier eBooks”
May 2023 in “General and comparative endocrinology” This study found that hair cortisol concentrations in rhesus macaques were not significantly correlated with hair growth rate, suggesting that cortisol-mediated inhibition of hair growth does not explain higher cortisol levels within the non-stress range.
September 2022 in “The American journal of dermatopathology/American journal of dermatopathology” In this pilot study, researchers found no sunscreen particles in the hair follicle units of patients with frontal fibrosing alopecia, suggesting no direct link between sunscreen use and the condition.
June 2022 in “Biomedical reports” This study concluded that STK11 gene polymorphisms were not predictive of metformin response in women with PCOS, though they may influence alopecia and hirsutism.
October 2021 in “International journal of basic and clinical pharmacology” This case report discusses how trichomegaly, an adverse effect of the cancer therapy drug erlotinib, might serve as a marker of positive tumor response and potentially aid in treating madarosis.